Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This study is to assess the safety and tolerability of sofosbuvir (SOF) 400 mg with and
without ribavirin (RBV) and/or with and without pegylated interferon alfa-2a (PEG) in
subjects with genotype 1, 2 or 3 hepatitis C (HCV) infection.
Phase:
Phase 2
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Interferons Ledipasvir Ledipasvir, sofosbuvir drug combination Ribavirin Sofosbuvir